New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Boston Scientific has received FDA approval for the REBEL Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease. Bare-metal stents continue to play an important role in the treatment of CAD and represent a significant portion of the global stent market. The company announced CE Mark for the Rebel Stent System in February. The REBEL Stent System expands the Boston Scientific family of stents featuring its proprietary platinum chromium alloy and a customized stent architecture design. The REBEL Stent offers the identical stent platform as the Promus PREMIER Drug-Eluting Stent but without the Everolimus drug.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
12:35 EDTBSXBoston Scientific CEO says M&A an important strategy
Boston Scientific CEO is speaking in a CNBC interview.
07:25 EDTBSXPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
09:04 EDTBSXBoston Scientific initiates study to assess EMBLEM S-ICD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use